NEO-POLYCIN
NEO-POLYCIN
23764466-adbe-4c9c-be60-3b09458d634e
HUMAN PRESCRIPTION DRUG LABEL
Sep 26, 2012
Rebel Distributors Corp
DUNS: 118802834
Products 1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (5)
Drug Labeling Information
INDICATIONS & USAGE SECTION
INDICATIONS AND USAGE:
Neo-PolycinTM Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis, and keratoconjunctivitis, blepharitis and blepharoconjunctivitis.
CONTRAINDICATIONS SECTION
CONTRAINDICATIONS:
Neo-PolycinTM Ophthalmic Ointment is contraindicated in individuals who have shown hypersensitivity to any of its components.
MICROBIOLOGY SECTION
Microbiology:
Neomycin sulfate, polymyxin B sulfate, and bacitracin zinc together are considered active against the following microorganisms: Staphylococcus aureus, streptococci including Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. The product does not provide adequate coverage against Serratia marcescens .
PRECAUTIONS SECTION
PRECAUTIONS:
General:
As with other antibiotic preparations, prolonged use of neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment may result in overgrowth of nonsusceptible organisms including fungi. If superinfection occurs, appropriate measures should be initiated. Bacterial resistance to neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment may also develop. If purulent discharge, inflammation, or pain becomes aggravated, the patient should discontinue use of the medication and consult a physician. There have been reports of bacterial keratitis associated with the use of topical ophthalmic products in multiple-dose containers which have been inadvertently contaminated by patients, most of whom had a concurrent corneal disease or a disruption of the ocular epithelial surface (seePRECAUTIONS: Information for Patients). Allergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future infections: Kanamycin, paromomycin, streptomycin, and possibly gentamicin.
Information for Patients:
Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, eyelid, fingers, or any other surface. The use of this product by more than one person may spread infection. Patients should also be instructed that ocular products, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated products (seePRECAUTIONS: General). If the condition persists or gets worse, or if a rash or allergic reaction develops, the patient should be advised to stop use and consult a physician. Do not use this product if you are allergic to any of the listed ingredients. Keep tightly closed when not in use. Keep out of reach of children.
Carcinogenesis, Mutagenesis, Impairment of Fertility:
Long-term studies in animals to evaluate carcinogenic or mutagenic potential have not been conducted with polymyxin B sulfate or bacitracin. Treatment of cultured human lymphocytes in vitro with neomycin increased the frequency of chromosome aberrations at the highest concentration (80 µg/mL) tested; however, the effects of neomycin on carcinogenesis and mutagenesis in humans are unknown. Polymyxin B has been reported to impair the motility of equine sperm, but its effects on male or female fertility are unknown. No adverse effects on male or female fertility, litter size, or survival were observed in rabbits given bacitracin zinc 100 gm/ton of diet.
Pregnancy:
Teratogenic Effects: Pregnancy Category C.
Animal reproduction studies have not been conducted with neomycin sulfate, polymyxin B sulfate or bacitracin. It is also not known whether neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Neoymcin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment should be given to a pregnant woman only if clearly needed.
Nursing Mothers:
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment is administered to a nursing woman.
Pediatric Use:
Safety and effectiveness in pediatric patients have not been established.
Geriatric Use:
No overall differences in safety or effectiveness have been observed between elderly and younger patients.
HOW SUPPLIED SECTION
HOW SUPPLIED:
Neo-PolycinTM Ophthalmic Ointment is supplied in 3.5 g (1/8 oz) sterile tamper evident tubes with ophthalmic tip.
NDC 42254-302-35
Store at 20o-25oC (68o-77oF) [See USP Controlled room temperature].
Neo-Polycin is a Trademark of Fera Pharmaceuticals, LLC.
FERA
Mfd. for:
Fera Pharmaceuticals, LLC
Locust Valley, NY 11560
Repackaged by:
** Rebel Distributors Corp.**
Thousand Oaks, CA 91320